UNSPSC 51351508: Medrogestone

This classification denotes a therapeutic progestin with the molecular formula C23H32O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 077DN93G5B, chemically known as 6,17-dimethylpregna-4,6-diene-3,20-dione but generally known as medrogestone, which bears US NIH Compound Identifier 13790. European Medicines Agency schedules Medrogestone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08696MIG. The term MEDROGESTONE is an International Non-Proprietary Name.

UNSPSC 51351508 Medrogestone, a Commodity code, covers pharmaceutical active pharmaceutical ingredients and finished pharmaceutical products supplied through cooperative purchasing vehicles to state and local health systems and government facilities. State and local governments procure under this code primarily through multistate purchasing cooperatives that aggregate demand across dozens of participating jurisdictions, establishing blanket agreements with manufacturers and pharmaceutical distributors to supply generic pharmaceuticals and over-the-counter products at negotiated pricing. The issuing bodies are typically state departments of administration or procurement offices administering cooperative purchasing alliances on behalf of member states, counties, and municipalities; individual health departments and correctional systems within those jurisdictions then draw supplies from the established contracts rather than issuing separate solicitations.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued an RFP on January 20, 2026 (S1070000015802) to establish multiple contracts for generic multi-source pharmaceuticals and OTC products effective July 1, 2026, with responses due March 26, 2026. The procurement spans participating state and local facilities in Minnesota, Oregon, and other MMCAP member jurisdictions. Vendors must supply products through three authorized wholesalers (AmerisourceBergen Drug Corporation/Cencora, Cardinal Health 110 and 112, and Morris & Dickson Co., LLC), hold cGMP and DSCSA compliance certifications, maintain relationships with at least two of the three wholesalers with chargeback systems in place, and provide pricing in formats including flat price, net price (NF30, NF60, NF90), or WAC-minus structures. Evaluation is weighted heavily toward price competitiveness (75 percent), with secondary weight on fixed pricing (10 percent), EDI capability (5 percent), administrative fee format compliance (5 percent), and a 3 percent administrative fee agreement (5 percent). Insurance requirements include $5,000,000 commercial general liability per occurrence, $2,000,000 network security and privacy liability, and $2,000,000 professional liability. The contract term runs two years for new vendors, with optional MMCAP-discretionary extensions.